IRIS
SVICHER, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 44.831
AS - Asia 7.952
EU - Europa 6.527
SA - Sud America 1.151
Continente sconosciuto - Info sul continente non disponibili 897
AF - Africa 152
OC - Oceania 107
Totale 61.617
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 44.514
SG - Singapore 4.069
IT - Italia 1.382
CN - Cina 1.323
BR - Brasile 933
DE - Germania 817
RU - Federazione Russa 815
HK - Hong Kong 674
VN - Vietnam 574
SE - Svezia 535
UA - Ucraina 511
FR - Francia 493
IE - Irlanda 451
PL - Polonia 395
FI - Finlandia 374
BD - Bangladesh 326
GB - Regno Unito 324
KR - Corea 242
JP - Giappone 227
CA - Canada 160
IN - India 130
AU - Australia 100
NL - Olanda 96
ES - Italia 93
AR - Argentina 75
MX - Messico 70
ID - Indonesia 62
TR - Turchia 54
BE - Belgio 51
AT - Austria 47
CZ - Repubblica Ceca 47
IQ - Iraq 44
ZA - Sudafrica 42
CO - Colombia 37
EC - Ecuador 36
PH - Filippine 34
JM - Giamaica 31
PK - Pakistan 21
VE - Venezuela 20
AE - Emirati Arabi Uniti 19
MA - Marocco 19
CL - Cile 18
UZ - Uzbekistan 17
CH - Svizzera 16
KE - Kenya 15
MY - Malesia 14
IL - Israele 13
EG - Egitto 12
RO - Romania 12
SA - Arabia Saudita 12
LT - Lituania 11
NG - Nigeria 11
PE - Perù 11
NP - Nepal 10
PY - Paraguay 10
TN - Tunisia 10
TW - Taiwan 10
DZ - Algeria 9
EU - Europa 9
JO - Giordania 9
KZ - Kazakistan 9
CR - Costa Rica 8
HN - Honduras 8
PT - Portogallo 8
TH - Thailandia 8
BB - Barbados 7
BG - Bulgaria 7
GT - Guatemala 7
IR - Iran 7
NZ - Nuova Zelanda 7
OM - Oman 7
AL - Albania 6
DO - Repubblica Dominicana 6
UY - Uruguay 6
DK - Danimarca 5
ET - Etiopia 5
SK - Slovacchia (Repubblica Slovacca) 5
UG - Uganda 5
AO - Angola 4
CM - Camerun 4
GR - Grecia 4
KG - Kirghizistan 4
MN - Mongolia 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AZ - Azerbaigian 3
BO - Bolivia 3
CI - Costa d'Avorio 3
GE - Georgia 3
KH - Cambogia 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
PS - Palestinian Territory 3
QA - Qatar 3
RS - Serbia 3
AM - Armenia 2
Totale 60.690
Salva come PNG Salva come JPEG
Città #
Woodbridge 11.094
Wilmington 10.920
Houston 8.885
Singapore 1.956
Fairfield 1.444
Ashburn 1.084
San Jose 1.041
Ann Arbor 913
Chandler 840
Hong Kong 660
Seattle 588
Beijing 533
Council Bluffs 531
Cambridge 460
Rome 442
Jacksonville 422
Dublin 398
New York 360
Kraków 324
Santa Clara 317
Medford 283
Dearborn 275
Los Angeles 268
Helsinki 248
The Dalles 231
Tokyo 190
Ho Chi Minh City 188
Milan 157
Buffalo 147
Hanoi 146
Lawrence 135
Dallas 115
Moscow 109
Munich 109
San Diego 102
São Paulo 96
Sunnyvale 89
Menlo Park 85
Nuremberg 80
Lauterbourg 77
Orem 73
Chicago 70
Boardman 65
Mülheim 65
Phoenix 61
San Francisco 61
London 60
Zhengzhou 60
Brussels 50
Warsaw 48
Jakarta 46
Brooklyn 45
Creede 44
Montreal 42
Denver 41
Chennai 40
Atlanta 38
Naples 38
North Bergen 38
Stockholm 37
Palo Alto 36
Toronto 36
Redondo Beach 34
Frankfurt am Main 33
Sydney 33
Poplar 32
Engelhard 31
Melbourne 31
Mexico City 30
La Veta 29
Amsterdam 28
Dong Ket 28
Columbus 27
Johannesburg 27
Rio de Janeiro 27
Washington 26
Brno 25
Haiphong 25
University Park 25
Bari 24
Guangzhou 24
Redwood City 24
Cedarhurst 23
Verona 23
Vienna 23
Canberra 22
Falls Church 22
Boston 21
Nanjing 21
Shanghai 21
Kingston 20
Lappeenranta 20
Olomouc 20
Madrid 19
Colorado Springs 18
Da Nang 18
Manchester 18
Quito 18
Curitiba 17
Baghdad 16
Totale 48.359
Salva come PNG Salva come JPEG
Nome #
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 595
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 587
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 580
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 573
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 554
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 537
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 537
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 536
Therapeutic strategies towards HIV-1 infection in macrophages 519
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 517
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 516
Understanding HIV compartments and reservoirs 501
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 498
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 497
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 492
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 490
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 489
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 488
Novel drug resistance mutations in HIV: Recognition and clinical relevance 486
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 486
HIV-1-associated dementia during HAART therapy 484
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 484
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 480
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 478
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 478
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 478
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 476
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 475
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 474
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 473
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 472
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 472
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 471
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 468
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 467
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 467
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 463
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 461
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 457
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 456
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 453
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 451
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 450
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 450
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme 448
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 447
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 447
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 447
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 446
Complete hbv prophylaxis withdrawal in HBsAg-positive liver transplant recipients after long-term minimal immunosuppression 446
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 445
Dynamics of NRTI resistance mutations during therapy interruption 443
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 443
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 443
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 442
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 442
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 436
Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage 436
Highlights on HIV eradication in 2013 436
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 434
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 433
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 432
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 431
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 431
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 431
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 428
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 427
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 424
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 423
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 422
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 422
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 420
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 419
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 419
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 418
The role of HIV infection in neurologic injury 416
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 414
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 413
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 413
Temporal change in the use of genotypic resistance testing over the years 1999--2003 412
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors 410
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 410
Does residual virus replication during successful HAART lead to HIV-1 genetic evolution? 407
Impact of pre-therapy viral load on virological response to modern first-line HAART 406
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 406
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 404
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype 403
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 403
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 402
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 400
Selected Amino Acid Mutations in HIV-1 B Subtype gp41 are Associated with Specific gp120v3 Signatures in the Regulation of Co-Receptor Usage 394
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 393
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 386
Papillomavirus and cervical cancer: Epidemiology, genetics and prevention [Il papillomavirus umano e il cancro della cervice uterina: Epidemiologia, basi genetiche e prevenzione] 384
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 382
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 376
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 371
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 370
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 369
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 369
Totale 45.090
Salva come PNG Salva come JPEG
Categoria #
all - tutte 159.299
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.299
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.622 0 0 118 97 80 163 86 78 365 145 74 416
2022/20232.309 250 196 145 267 192 465 162 225 182 33 155 37
2023/20241.272 223 35 113 61 123 198 62 24 77 142 25 189
2024/20255.914 175 1.071 499 344 221 396 563 259 612 328 746 700
2025/202610.130 882 417 921 910 941 448 1.259 1.245 1.186 853 566 502
2026/20271.453 568 646 239 0 0 0 0 0 0 0 0 0
Totale 61.617